Skip to main content
Year archive

SYNTARA LIMITED — 2022 filings

All 95 regulatory filings released by SYNTARA LIMITED (SNT) in 2022, sourced directly from the official regulator.

95 Filings
2022 Period
2022 filings (95)
Filing Released Lang
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change
2022-12-21 English
Pharmaxis Skin Scarring Study Fully Recruited 2 pages 172.2KB
Regulatory Filings
2022-12-20 English
Change in substantial holding 3 pages 169.5KB
Major Shareholding Notification
2022-12-13 English
Pharmaxis Appoints Dr Simon Green as Director 2 pages 112.0KB
Board/Management Information
2022-12-13 English
Initial Director's Interest Notice 2 pages 139.1KB
Director's Dealing
2022-12-13 English
Application for quotation of securities - PXS 6 pages 27.9KB
Capital/Financing Update
2022-12-11 English
PXS Drug Profiled American Society of Hematology Conference 3 pages 199.7KB
Regulatory Filings
2022-12-11 English
Change in substantial holding 6 pages 171.1KB
Major Shareholding Notification
2022-12-07 English
Becoming a substantial holder 3 pages 631.7KB
Major Shareholding Notification
2022-12-06 English
Change in substantial holding 4 pages 177.4KB
Regulatory Filings
2022-12-05 English
Section 708(5)(e) Notice 1 page 145.3KB
Capital/Financing Update
2022-12-04 English
Application for quotation of securities - PXS 5 pages 25.9KB
Share Issue/Capital Change
2022-12-01 English
Notification regarding unquoted securities - PXS 7 pages 30.8KB
Share Issue/Capital Change
2022-12-01 English
Change of Director's Interest Notice 3 pages 150.0KB
Director's Dealing
2022-12-01 English
Change of Director's Interest Notice 3 pages 148.1KB
Director's Dealing
2022-12-01 English
Change of Director's Interest Notice 2 pages 145.1KB
Director's Dealing
2022-12-01 English
Ceasing to be a substantial holder 2 pages 629.4KB
Major Shareholding Notification
2022-12-01 English
CEO Presentation to 2022 AGM 20 pages 2.1MB
AGM Information
2022-11-28 English
Chairman's Address to Shareholders 3 pages 181.7KB
AGM Information
2022-11-28 English
Results of Meeting 2 pages 219.0KB
Declaration of Voting Results & Voting Rights Announcements
2022-11-28 English
Notification regarding unquoted securities - PXS 6 pages 28.1KB
Share Issue/Capital Change
2022-11-28 English
Change of Director's Interest Notice 2 pages 143.9KB
Director's Dealing
2022-11-28 English
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change
2022-11-22 English
Investor Presentation 28 pages 1.9MB
Investor Presentation
2022-11-08 English
Application for quotation of securities - PXS 6 pages 28.3KB
Share Issue/Capital Change
2022-11-06 English
Application for quotation of securities - PXS 6 pages 28.4KB
Share Issue/Capital Change
2022-10-31 English
Change of Director's Interest Notice 2 pages 146.8KB
Director's Dealing
2022-10-31 English
Application for quotation of securities - PXS 7 pages 29.7KB
Share Issue/Capital Change
2022-10-31 English
Change of Director's Interest Notice 2 pages 149.9KB
Director's Dealing
2022-10-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 5 pages 225.9KB
Interim / Quarterly Report
2022-10-30 English
Quarterly Activities Report 13 pages 872.6KB
Interim / Quarterly Report
2022-10-30 English
Change in substantial holding 4 pages 185.2KB
Major Shareholding Notification
2022-10-27 English
Notice of Annual General Meeting/Proxy Form 22 pages 435.1KB
AGM Information
2022-10-27 English
Annual Report to shareholders 72 pages 1.2MB
Annual Report
2022-10-27 English
Appendix 4G 14 pages 190.2KB
Regulatory Filings
2022-10-27 English
Corporate Governance Statement 19 pages 194.0KB
Governance Information
2022-10-27 English
Becoming a substantial holder 3 pages 88.8KB
Major Shareholding Notification
2022-10-27 English
Becoming a substantial holder 4 pages 259.3KB
Regulatory Filings
2022-10-26 English
Application for quotation of securities - PXS 6 pages 27.5KB
Share Issue/Capital Change
2022-10-25 English
Section 708A(5)(e) Notice 1 page 145.3KB
Capital/Financing Update
2022-10-25 English
Placement 3 pages 230.9KB
Capital/Financing Update
2022-10-18 English
Investor Presentation 43 pages 1.6MB
Investor Presentation
2022-10-18 English
PXS announces positive interim data from myelofibrosis trial 3 pages 265.0KB
Capital/Financing Update
2022-10-18 English
Proposed issue of securities - PXS 5 pages 27.9KB
Capital/Financing Update
2022-10-18 English
Proposed issue of securities - PXS 5 pages 28.2KB
Capital/Financing Update
2022-10-18 English
Notification regarding unquoted securities - PXS 7 pages 29.7KB
Share Issue/Capital Change
2022-10-17 English
Proposed Issue of Securities to Chief Executive Officer 2 pages 164.4KB
Capital/Financing Update
2022-10-17 English
Trading Halt 2 pages 383.5KB
Capital/Financing Update
2022-10-17 English
PXS Releases Promising Interim Data from Skin Scarring Study 3 pages 182.6KB
Interim / Quarterly Report
2022-09-25 English
Investor Presentation Interim Data from Skin Scarring Study 9 pages 1.1MB
Investor Presentation
2022-09-25 English
Date of Virtual AGM and Date for Director Nominations 1
AGM Information
2022-09-12 English
Investor presentation 16 pages 1.1MB
Investor Presentation
2022-09-05 English
PXS to Receive Stg2.9m from Parkinsons UK for New Trial 4 pages 203.8KB
Capital/Financing Update
2022-08-31 English
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change
2022-08-31 English
Preliminary Final Report 65 pages 895.0KB
Annual Report
2022-08-29 English
Notification of cessation of securities - PXS 4 pages 24.4KB
Regulatory Filings
2022-08-22 English
Change of Director's Interest Notice 2 pages 148.8KB
Director's Dealing
2022-08-22 English
Notification of cessation of securities - PXS 4 pages 24.2KB
Regulatory Filings
2022-08-21 English
Pharmaxis Receives Aptar Option Exercise Fees of US$5m 2 pages 107.9KB
Capital/Financing Update
2022-08-15 English
Director Appointment/Resignation 2 pages 113.7KB
Board/Management Information
2022-08-04 English
Final Director's Interest Notice 2 pages 117.1KB
Director's Dealing
2022-08-04 English
Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology 3 pages 167.6KB
Capital/Financing Update
2022-08-03 English
Quarterly Appendix 4C Cash Flow Report 5 pages 206.1KB
Interim / Quarterly Report
2022-07-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 480.0KB
Interim / Quarterly Report
2022-07-28 English
Investor presentation 20 pages 1.9MB
Investor Presentation
2022-07-28 English
Investor presentation for quarterly shareholder update 7 pages 910.9KB
Investor Presentation
2022-07-28 English
Pharmaxis Quarterly Shareholder Update and Investor Briefing 2 pages 126.5KB
Regulatory Filings
2022-07-25 English
Results of Meeting 2 pages 182.6KB
Declaration of Voting Results & Voting Rights Announcements
2022-07-10 English
Appointment of Dr Jana Baskar as Chief Medical Officer 3 pages 112.5KB
Board/Management Information
2022-06-30 English
Notification regarding unquoted securities - PXS 6 pages 28.0KB
Share Issue/Capital Change
2022-06-30 English
Application for quotation of securities - PXS 6 pages 27.9KB
Share Issue/Capital Change
2022-06-14 English
Notice of General Meeting/Proxy Form 9 pages 330.1KB
Proxy Solicitation & Information Statement
2022-06-07 English
Notification of cessation of securities - PXS 4 pages 24.2KB
Regulatory Filings
2022-05-29 English
Application for quotation of securities - PXS 6 pages 27.9KB
Share Issue/Capital Change
2022-05-29 English
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change
2022-05-29 English
Clarification Announcement 6 pages 287.0KB
Interim / Quarterly Report
2022-05-12 English
Appendix 4C Quarterly Cash Flow Report 4 pages 199.8KB
Interim / Quarterly Report
2022-04-28 English
Quarterly Activities Report 10 pages 484.5KB
Interim / Quarterly Report
2022-04-28 English
Investor Presentation 7 pages 928.9KB
Investor Presentation
2022-04-28 English
Pharmaxis Quarterly Investor Briefing 2 pages 126.2KB
Investor Presentation
2022-04-25 English
R&D Showcase Presentations Webinar 2 32 pages 4.9MB
Regulatory Filings
2022-03-30 English
R&D Showcase Presentations Webinar 1 62 pages 10.3MB
Investor Presentation
2022-03-28 English
Investor Presentation 20 pages 2.0MB
Investor Presentation
2022-03-21 English
PXS Investor R&D Showcase Webinars 2 pages 126.5KB
Investor Presentation
2022-03-17 English
PXS Launches New International Trial Sites in Cancer Trial 3 pages 116.7KB
Regulatory Filings
2022-03-16 English
Half Yearly Report and Accounts 24 pages 412.9KB
Interim / Quarterly Report
2022-02-10 English
Change in substantial holding 5 pages 174.8KB
Major Shareholding Notification
2022-02-10 English
First Patients Dosed in PXS Scar Reduction Trial 3 pages 139.3KB
Regulatory Filings
2022-01-30 English
Quarterly Appendix 4C Cash Flow Report 4 pages 200.1KB
Interim / Quarterly Report
2022-01-30 English
Quarterly Activities Report 13 pages 530.6KB
Interim / Quarterly Report
2022-01-30 English
Presentation - quarterly investor update 8 pages 1.1MB
Investor Presentation
2022-01-30 English
Updated Investor Presentation 20 pages 1.8MB
Investor Presentation
2022-01-30 English
PXS Quarterly Shareholder Update and Investor Briefing 2 pages 126.9KB
Investor Presentation
2022-01-26 English
Response to ASX Aware Query 7 pages 404.4KB
Regulatory Filings
2022-01-09 English
PXS Collaborators Receive Government Grants of $1.4m 3 pages 156.1KB
Regulatory Filings
2022-01-05 English